CASIF CASI Pharmaceuticals, Inc.
Listings ·
CASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern.
CASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States and throughout the world. The company was incorporated in 1991, and in 2012 it shifted its business strategy to China. Its operations are conducted mainly through two subsidiaries, CASI China, headquartered in Beijing, and CASI Wuxi. The company is focused on acquiring, developing and commercializing products in hematology oncology, autoimmune and organ transplant rejection, along with other unmet medical needs. CASI China oversees the company's sales and marketing of EVOMELA and FOLOTYN, and the anticipated commercial activities of its pipeline products, as well as NMPA regulatory activities. The company states that it had 205 full-time employees in China, including a commercial team of 128 hematology and oncology sales and marketing specialists. Because its business focus has shifted from ANDAs to hematology oncology, the company says a substantial investment in GMP manufacturing facilities does not fit its current focus.
| Product or program | What it is | Stage |
|---|---|---|
| EVOMELA | Product whose sales and marketing CASI China oversees | |
| FOLOTYN | Product whose sales and marketing CASI China oversees |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $20.7 million | $28.5 million |
| Research and development | $6.3 million | $8.9 million |
| Net income (loss) | -$48.1 million | -$39.3 million |
| Cash from operations | -$20.8 million | -$29.2 million |
| Cash and equivalents | $5.6 million | $13.5 million |
Our latest story on this, dated Aug 14, 2026: "CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 14, 2026: "CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote". The story links the filing or release it is based on. Read the story.
CASI Pharmaceuticals, Inc. trades under the ticker CASIF on OTC.
CASI Pharmaceuticals, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for CASI Pharmaceuticals, Inc. is 1962738. Its filings are on SEC EDGAR.
20,555,873 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15.
Our directory records CASI Pharmaceuticals, Inc. under China.
Our directory classifies CASI Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for CASI Pharmaceuticals, Inc. is KYG1933S1012.
aibio.space lists CASI Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States and throughout the world. The company was incorporated in 1991, and in 2012 it shifted its business strategy to China.
EVOMELA: Product whose sales and marketing CASI China oversees
FOLOTYN: Product whose sales and marketing CASI China oversees
$20.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio